Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Ajay V. Maker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8234-2762; OpenAlex author ID A5038444710. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Survival after resection of pancreatic cancer is similar with neoadjuvant gemcitabine-nab-paclitaxel or mFOLFIRINOX but one size will not fit all in the future. First author DOI 10.21037/hbsn-2025-1-952↗
  2. Robotic pancreatectomy for pancreatic adenocarcinoma: evolving trends in patient selection and practice patterns across a decade. Co-author DOI 10.1016/j.hpb.2025.06.009↗
  3. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27695↗
  4. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
  5. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-024-15841-5↗
  6. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/curroncol31090370↗
  7. ASO Author Reflections: How Can We Improve the Postoperative Experience for Our Pancreatic Cancer Patients? A Practical Technique to Optimize Pain Control Afte… Co-author DOI 10.1245/s10434-020-09092-3↗
  8. Impact of Immunotherapy after Resection of Pancreatic Cancer. Last author DOI 10.1016/j.jamcollsurg.2019.01.016↗
  9. KRAS G12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Co-author DOI 10.1038/s41598-018-30916-6↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sophia Hernandez · 1 shared paper, 2026 · strength 0.63
  2. Mohamed A. Adam · 3 shared papers, 2024 · strength 0.57
  3. Adnan A. Alseidi · 3 shared papers, 2024 · strength 0.57
  4. Eric K. Nakakura · 3 shared papers, 2024 · strength 0.57
  5. Kimberly Saunders Kirkwood · 3 shared papers, 2024 · strength 0.57
  6. Paul Wong · 2 shared papers, 2024–2025 · strength 0.51
  7. Jane Wang · 2 shared papers, 2024 · strength 0.36
  8. Laleh Golkar Melstrom · 1 shared paper, 2025 · strength 0.30
  9. Yuman Fong MD · 1 shared paper, 2025 · strength 0.30
  10. Han Yin · 1 shared paper, 2024 · strength 0.18
  11. June S. Peng · 1 shared paper, 2024 · strength 0.18
  12. Amir Ashraf‐Ganjouei · 1 shared paper, 2024 · strength 0.18
  13. Timothy R. Donahue · 1 shared paper, 2024 · strength 0.18
  14. Andrew H. Ko · 1 shared paper, 2024 · strength 0.18
  15. Jennifer Brooke Valerin · 1 shared paper, 2024 · strength 0.18
  16. Lauren M. Perry · 1 shared paper, 2024 · strength 0.18
  17. Phoebe N. Miller · 1 shared paper, 2024 · strength 0.18
  18. Sunhee S. Kim · 1 shared paper, 2024 · strength 0.18
  19. Richard J. Bold · 1 shared paper, 2024 · strength 0.18
  20. Grace Kim · 1 shared paper, 2024 · strength 0.18
  21. Parisa Oviedo · 1 shared paper, 2024 · strength 0.18
  22. Claudia Rosso · 1 shared paper, 2024 · strength 0.18
  23. Margaret A. Tempero · 1 shared paper, 2024 · strength 0.18
  24. Rebekah Ruth White · 1 shared paper, 2024 · strength 0.18
  25. Thuy B. Tran · 1 shared paper, 2019 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.